

Design and Synthesis of Novel Hyperforin Analogues

K. P. Mitsopoulou, V. P. Vidali, E. A. Couladouros*

Chemistry Laboratories, Agricultural University of Athens, Iera Odos 75, Athens, 118 55

Laboratory of Natural Products Synthesis and Bioorganic Chemistry, NCSR 'Demokritos' 153 10 Ag. Paraskevi, Attikis, Greece

e-mail: ecoula@chem.demokritos.gr

Hyperforin, the most known member of this family, has been isolated from *Hypericum perforatum* (St. Johns's wort), known for its antidepressant and anticancer properties. There is a big interest in synthesizing Hyperforin's analogues in order to improve the molecule's activity.[1,3] Up-to-date analogues showing highest biological activity possess an enol hydroxyl free [3g-i]. Based on this literature background, our efforts focus on the design and synthesis of new analogues with improved properties. In our lab, a new short biomimetic approach has been developed leading to the fully functionalized bicyclic core of type A acylphloroglucinols, including Hyperforin.[2] Based on this strategy we targeted in two classes of compounds possessing either an sp^2- or an sp^3-carbon on C-7, starting from key intermediate **1**. A general route leading to 1 is depicted on Scheme 2. Thus, deacetylation of aldehyde Ac-**1**, led to analogue **2**, which after Michael and Wittig afforded sp^3 C-7 analogues **3** and **4**, respectively (Scheme 3). Approaches to more sp^2 C-7 analogues including either Wittig on Ac-**1** (Approach I, Scheme 4) or deprotection after Wittig on Pv-**1** led to no desirable results (Approach II). Thus, approach III was attempted, based on establishing the desirable side chain functionalization before alkylation step. Preliminary efforts for synthesis of chloride **5** from diol **6** led to degradation products. Biological activity results obtained from our first derivatives will lead our design to a new generation of hyperforin analogues. Moreover, our efforts focus on the improvement of efficiency of our methodology.

Scheme 1. Retrosynthetic Scheme



Scheme 2. General synthetic scheme of Hyperforin's analogues



Scheme 3. An example of the synthesis of Hyperforin's analogues



Scheme 4. Attempts to synthesize more sp^2-C-7 analogues



Approach III (Establishment of target unsaturated side chain, before alkylation step)



Synthesis of side chain



References

1. Mennini, T. et al *Lifi Sci.* **2004**, *75*, 1021.
2. Elias A. Couladouros, Marianna Dakanali, Konstantinos D. Demadis and Veroniki P. Vidali *Org. Lett.*, **2009**, *11*, 4430.
3. a. Kraus, G. A. et al. *Tetrahedron* **2005**, *61*, 2111, b. Nicolaou, K. C. et al *Angew. Chem. Int. Ed. Engl.* **2005**, *44*, 3895, c. Young, D. G. et al *J. Org. Chem.* **2002**, *67*, 3134, d. Mehta, G. et al *Tet. Lett.* **2004**, *45*, 1113, e. Stoltz, B. M. et al *Org. Lett.* **2002**, *4*, 1943, f. Grossman, R. B. et al *Org. Lett.* **2003**, *5*, 4619, g. Ciochina R. et al. Chem. Rev. **2006**, 106, 3963, h. Verotta et al. J. Nat. Prod. **1999**, 62, 770, i. Verotta et al. J. Nat. Prod. **2000**, 63, 412.

Acknowledgments

We would like to thank Prof. A. Giannis from the University of Leipzig for kindly obtained HRMS for most of the compounds presented here, as well as for testing their biological activity. Also, we would like to thank the Research Funding Program: Heracleitus II